Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and ...

Neuroinflammation represents a hallmark of many degenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, amyotrophic lateral sclerosis, multiple sclerosis, multiple system atrophy and ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

Research studying the effects of cannabis on the brain has often focused on adolescents, but a new study from CU Anschutz ...

X FACTOR legend Chico Slimani has revealed how he bounced back from “losing everything” after falling victim to a Dubai ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

The UAE is rapidly consolidating its position as a global pharmaceutical and life sciences hub, with the national market ...

Annexon (ANNX) stock: high-risk biotech upside from tanruprubart (GBS) & vonaprument (geographic atrophy). Read here for a ...

When answers arrive preformed, that developmental pressure disappears. Children still learn, but they may be learning ...

Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.

Ethics rarely collapse in a dramatic moment. They erode. Quietly. Increment by increment. Often with good intentions. In ...